外周血生物标志物在非小细胞肺癌免疫治疗疗效预测研究进展

Progress of Peripheral Blood Biomarkers in Predicting the Efficacy of Immunotherapy for Non-Small Cell Lung Cancer

近年来,以免疫检查点抑制剂(ICIs)为代表的免疫治疗在非小细胞肺癌(NSCLC)综合治疗中已经取得重大突破,彻底更改了不同期别NSCLC的整体治疗策略。虽然肿瘤组织相关标记物如:细胞程序性死亡–配体1 (PD-L1)、肿瘤突变负荷(TMB)等能在一定程度上很好的预测应答反应;但受制于肿瘤标本获取、检测技术、经济负担等因素,限制其在临床大规模应用,如何早期、高效、无创的识别免疫治疗的潜在获益人群是当务之急。外周血成为理想的样本来源,也显示了作为免疫治疗效果预测因子的潜力。本文旨在综述外周血生物标志物在NSCLC免疫治疗疗效预测研究进展,为后续临床治疗提供参考依据。

In recent years, immunotherapy represented by immune checkpoint inhibitors (ICIs) has made significant breakthroughs in the comprehensive treatment of non-small cell lung cancer (NSCLC), completely changing the overall treatment strategy of NSCLC of different stages. Although tumor tissue-associated markers such as programmed cell death-ligand 1 (PD-L1) and tumor mutational load (TMB) can predict response well to a certain extent;however, factors such as tumor specimen acquisition, detection technology, and economic burden limit their large-scale clinical application, and it is imperative to identify the potential beneficiary populations of immunotherapy in an early, efficient, and non-invasive manner. Peripheral blood has become an ideal sample source and has also shown potential as a predictor of immunotherapy efficacy. The aim of this article is to review the progress of peripheral blood biomarkers in NSCLC immunotherapy efficacy prediction research, and provide a reference basis for subsequent clinical treatment.